Alexion Pharmaceuticals, Inc. (ALXN) — Financial statements
Income statement, balance sheet, and cash flow for Alexion Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 6,070↑21.6% | 4,991↑20.8% | 4,131↑16.3% | 3,551↑15.1% | 3,084 | |
| Cost of Revenue | 554↑40.3% | 395↑5.4% | 374↓17.6% | 454↑76.0% | 258 | |
| Gross Profit | 5,516↑20.0% | 4,597↑22.4% | 3,757↑21.3% | 3,097↑9.6% | 2,826 | |
| Operating Expenses | ||||||
| R&D Expenses | 1,003↑13.2% | 886↑21.3% | 730↓16.8% | 878↑16.0% | 757 | |
| General & Administrative Expenses | 1,400↑11.0% | 1,261↑13.4% | 1,112↑1.6% | 1,094↑14.7% | 954 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 1,400↑11.0% | 1,261↑13.4% | 1,112↑1.6% | 1,094↑14.7% | 954 | |
| Other Expenses | 254↓18.1% | 310↓3.3% | 320↑0.0% | 320↓0.6% | 322 | |
| Operating Expenses | 2,657↑8.1% | 2,457↑13.6% | 2,162↓5.7% | 2,293↑12.8% | 2,033 | |
| Total Costs & Expenses | 3,210↑12.6% | 2,851↑12.4% | 2,537↓7.7% | 2,747↑19.9% | 2,291 | |
| Operating Results | ||||||
| Operating Income | 2,860↑33.6% | 2,140↑34.2% | 1,595↑98.3% | 804↑1.4% | 793 | |
| Depreciation & Amortization | 329↓12.6% | 377↓7.0% | 405↓18.4% | 497↑25.4% | 396 | |
| EBITDA | 1,003↓61.9% | 2,633↑253.1% | 746↓34.8% | 1,143↑6.9% | 1,069 | |
| EBIT | 674↓70.1% | 2,257↑562.9% | 340↓47.3% | 646↓4.0% | 673 | |
| Interest & Other Income | ||||||
| Net Interest Income | -105↓34.6% | -78↑20.8% | -98↑0.2% | -98↓1.4% | -97 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 105↑34.6% | 78↓20.8% | 98↓0.2% | 98↑1.4% | 97 | |
| Non-Operating Income | 2,186↑1973.4% | -117↓109.3% | 1,254↑694.8% | 158↑31.5% | 120 | |
| Other Income / Expenses | -2,291↓5989.2% | 39↑102.9% | -1,352↓427.9% | -256↓18.1% | -217 | |
| Income Before Tax | 569↓73.9% | 2,179↑799.6% | 242↓55.8% | 548↓4.9% | 576 | |
| Income Tax Expense | -34↑84.7% | -226↓237.0% | 165↑57.5% | 105↓41.0% | 177 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 603↓74.9% | 2,404↑2998.3% | 78↓82.5% | 443↑11.1% | 399 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 603↓74.9% | 2,404↑2998.3% | 78↓82.5% | 443↑11.1% | 399 | |
| Bottom-Line Net Income | 603↓74.9% | 2,404↑2998.3% | 78↓82.5% | 443↑11.1% | 399 | |
| EPS (Basic) | 2.75↓74.3% | 10.70↑2957.1% | 0.35↓82.3% | 1.98↑11.2% | 1.78 | |
| EPS (Diluted) | 2.75↓74.3% | 10.70↑2957.1% | 0.35↓82.2% | 1.97↑11.9% | 1.76 | |
| Weighted Average Shares | 219↓2.5% | 225↑0.1% | 225↑0.3% | 224↓0.0% | 224 | |
| Weighted Average Diluted Shares | 219↓2.5% | 225↑0.1% | 225↓0.4% | 225↓0.7% | 227 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.